Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EPS (Weighted Average and Diluted): 2023-2025

Historic EPS (Weighted Average and Diluted) for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$0.57.

  • CG Oncology's EPS (Weighted Average and Diluted) fell 90.00% to -$0.57 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.04, marking a year-over-year increase of 62.29%. This contributed to the annual value of -$1.41 for FY2024, which is 90.99% up from last year.
  • As of Q3 2025, CG Oncology's EPS (Weighted Average and Diluted) stood at -$0.57, which was down 5.56% from -$0.54 recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's EPS (Weighted Average and Diluted) peaked at -$0.28 during Q2 2024, and registered a low of -$4.47 during Q4 2023.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$1.69, with a median of -$0.54 in 2025.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 92.88% in 2024, then crashed by 92.86% in 2025.
  • CG Oncology's EPS (Weighted Average and Diluted) (Quarterly) stood at -$4.47 in 2023, then soared by 89.26% to -$0.48 in 2024, then tumbled by 90.00% to -$0.57 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.57 in Q3 2025, compared to -$0.54 in Q2 2025 and -$0.45 in Q1 2025.